Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

Bullboard Posts

Post by icecubeon Aug 26, 2015 9:52pm

59 Views

Post# 24054709

Can you smell truthseeker's fear?

I gave you the source. Log in and check for yourself.

icecube wrote:
Last Close
7.69 (CAD)
August 25, 2015
TORONTO Exchange
Avg Daily Vol
77,139
52-Week High
19.52
Trailing PE
13.0
Annual Div
--
ROE
25.6%
LTG Forecast
--
1-Mo Return
-36.0%
Market Cap
212M
52-Week Low
7.02
Forward PE
78.5
Dividend Yield
--
Annual Rev
36M
Inst Own
28.3%
3-Mo Return
-38.4%

Source: Thomson Reuters